The global burden of type 2 diabetes necessitates continuous innovation and reliable production of effective treatments. Linagliptin, a cornerstone in managing this chronic condition, owes its existence to a series of precisely synthesized chemical intermediates. Among these, 8-Bromo-3-methylxanthine, identified by CAS number 93703-24-3, plays an indispensable role. For pharmaceutical R&D professionals and procurement specialists, understanding this compound's properties and its manufacturers is key to successful drug development.

Chemical Profile of 8-Bromo-3-methylxanthine

Chemically known as 8-Bromo-3-methyl-3,7-dihydro-1H-purine-2,6-dione, this xanthine derivative is characterized by its molecular formula C6H5BrN4O2 and a molecular weight of 245.03. It typically presents as a white powder with a high purity of ≥99.0%, a critical attribute for its intended pharmaceutical applications. The compound's structure, featuring a bromine atom and a methyl group on the xanthine core, imparts specific reactivity essential for subsequent synthesis steps leading to Linagliptin.

The Synthesis Pathway to Linagliptin

Linagliptin is a potent and selective inhibitor of dipeptidyl peptidase-4 (DPP-4). By inhibiting DPP-4, it increases the levels of active incretins, thereby improving glucose-dependent insulin secretion and suppressing glucagon release, ultimately leading to better glycemic control. The synthesis pathway involves several complex chemical transformations, with 8-Bromo-3-methylxanthine serving as an early-stage precursor. The reliability of its supply and quality directly influences the efficiency and cost-effectiveness of the entire Linagliptin manufacturing process.

Choosing the Right Manufacturer

When seeking to buy 8-Bromo-3-methylxanthine, the choice of supplier is critical. Pharmaceutical companies require manufacturers who not only meet stringent purity standards but also offer consistent batch-to-batch quality and a stable supply chain. Look for suppliers who can provide comprehensive technical data, including CoA and, if necessary, support for regulatory filings. Factors such as competitive pricing, adherence to GMP principles (where applicable), and strong customer service are also vital considerations for a long-term partnership.

As a dedicated manufacturer of pharmaceutical intermediates, NINGBO INNO PHARMCHEM CO.,LTD. specializes in producing high-purity 8-Bromo-3-methylxanthine. We are committed to supporting the pharmaceutical industry's need for reliable, high-quality chemical building blocks. We invite you to reach out to our sales team to discuss your requirements and to obtain a quote for this essential intermediate.